Given their prominent role in tumour growth, invasion, and metastasis, the VEGFR and EGFR signaling pathway present feasible targets for pharmacologic intervention in NSCLC, and several agents have demonstrated encouraging antitumor activity. Here, EGFR is linked to non-small cell lung carcinoma.